Acetylon Pharmaceuticals Incorporated Report issue

For profit Phase 1 Phase 2
Founded: Boston MA United States (2008)
Status: Acquired by Celgene (2016) → now Bristol-Myers Squibb (2019)

Organization Overview

First Clinical Trial
2014
NCT02088398
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2016

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Active Ingredients

Drugs in Phase 2 Trials (1)

ricolinostat (5 trials)

Drugs in Phase 1 Trials (4)

bevacizumab (avastin) (1 trial)

ibrutinib (imbruvica) (1 trial)

idelalisib (zydelig) (1 trial)

paclitaxel (taxol) (2 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Breast Neoplasms (Phase 1)

Fallopian Tube Neoplasms (Phase 1)

Leukemia (Phase 1)

Leukemia, Lymphocytic, Chronic, B-Cell (Phase 1)

Leukemia, Lymphoid (Phase 1)

Lymphoma (Phase 2)

Neoplasms (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 5
  • # of Trial APIs: 5